Inverse agonists at the polyamine-sensitive modulatory site of the NMDA receptor: 50-fold increase in potency by insertion of an aromatic ring into an alkanediamine chain

European Journal of Medicinal Chemistry

Volumn 33, Issue 1, 1998, Pages 3-14

  Berger, Michael L ^a,b   Schödl, Clemens ^c   Noe, Christian R ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b GOETHE UNIVERSITY   (Germany)

^c VIENNA UNIVERSITY OF TECHNOLOGY   (Austria)

Author keywords

NMDA receptor; Polyamine; Polyamine inverse agonist; Thiophenedialkanamine; 3H MK 801 binding

Indexed keywords

1,12 DODECANEDIAMINE; DIAMINE; DIZOCILPINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; POLYAMINE; SPERMIDINE; SPERMINE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN; DRUG POTENCY; MALE; NONHUMAN; RAT; SYNTHESIS;

EID: 0031940414     PISSN: 02235234     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0223-5234(99)80070-1     Document Type: Article

References (29)

1. [1] Williams K., Romano C., Dichter M.A., Molinoff P.B., Life Sci. 48 (1991) 469-498.
2. [2] Johnson T.D., Trends Pharmacol. Sci. 17 (1996) 22-27.
3. [3] Williams K., Dawson V.L., Romano C., Dichter M.A., Molinoff P.B., Neuron 5 (1990) 199-208.
4. [4] Berger M.L., Seifriz I., Letschnig M., Schödl C., Noe C.R., Neurosci. Lett. 142 (1992) 85-88.
5. [5] Reynolds I.J., J. Pharmacol. Exp. Ther. 255 (1990) 1001-1007.
6. [6] Sacaan A.I., Johnson K.M., J. Pharmacol. Exp. Ther. 255 (1990) 1060-1063.
7. [7] Reynolds I.J., Baron B.M., Edwards M.L., J. Pharmacol. Exp. Ther. 259 (1991) 626-632.
8. [8] Reynolds I.J., Aizenman E., J. Neurosci. 12 (1992) 970-975.
9. [9] Maciver C.R., Bednar D.L., Karbon E.W., Neurosci. Lett. 132 (1991) 146-150.
10. [10] Donevan S.D., Jones S.M., Rogawski M.A., Mol. Pharmacol. 41 (1992) 727-735.
11. [11] Rock D.M., MacDonald R.L., Neurosci. Lett. 144 (1992) 111-115.
12. [12] Subramaniam S., Donevan S.D., Rogawski M.A., Neurosci. Lett. 147 (1992) 213-216.
13. [13] Carter C.J., Lloyd K.G., Zivkovic B., Scatton B., J. Pharmacol. Exp. Ther. 253 (1989) 475-482.
14. [14] Reynolds I.J., Miller R.J., Mol. Pharmacol. 36 (1989) 758-765.
15. [15] Benavides J., Peny B., Allen J., Scatton B., J. Pharmacol. Exp. Ther. 260 (1992) 896-901.
16. [16] Hashimoto K., Mantione C.R., Spada M.R., Neumeyer J.L., London E.D., Eur. J. Pharmacol. 266 (1994) 67-77.
17. [17] Romano C., Willianis K., DePriest S., Seshadri R., Marshall G.R., Israel M., Molinoff P.B., Mol. Pharmacol. 41 (1992) 785-792.
18. [18] Yoneda Y., Ogita K., Enomoto R., Kojima S., Shuto M., Shirahata A., Samejima K., Brain Res. 679 (1995) 15-24.
19. [19] Gol'dfarb Y.L., Taits S.Z., Belenkii L.I., Tetrahedron 19 (1963) 1851-1866.
20. [20] Cacniast P., Deluearche A., Comptes Rendus 222 (1946) 1301-1302.
21. [21] Badger G., Rodda H., Sasse W., J. Chem. Soc. (1954) 4162.
22. [22] Brenner M., Müller H.R., Pfister H.R., Helv. Chim. Acta 33 (1950) 568.
23. [23] Nordlander J.E., Payne M.J., Balk M.A., Gress J.L., Harris F.D., Lane J.S., Lewe R.F., Marshall S.E., Nagy D., Rachlin D.J., J. Org. Chem. 49 (1984) 136.
24. [24] Cheng Y-C., Prusoff W.H., Biochem. Pharmacol. 22 (1973) 3099-3108.
25. [25] Donkor I.O., Berger M.L., Bioorg. Med. Chem. Lett. 7 (1997) 1455-1460.
26. [26] Benveniste M., Mayer M.L., J. Physiol. 464 (1993) 131-163.
27. [27] Schödl C., Thesis, Technical University Vienna, Austria, 1994.
28. [28] Berger M.L., J. Pharmacol. Toxicol. Meth. 34 (1995) 79-88.
29. [29] Berger M.L., Charton G., Ben-Ari Y., J. Neurochem. 47 (1986) 720-727.